The NHS rollout of Mounjaro for weight management has introduced a new treatment option for eligible adults living with obesity in England. Mounjaro contains tirzepatide, a medicine that works on both GIP and GLP-1 receptors and is used alongside a reduced-calorie diet and increased physical activity when prescribed for weight management.
However, NHS access to Mounjaro is not available to everyone who meets a general BMI threshold. The rollout is being introduced gradually, with access prioritised according to clinical need and delivered through specialist weight management services and primary care.
For people in Manchester searching for information about NHS Mounjaro, understanding the current eligibility criteria, rollout stages and appropriate route to treatment is important before considering any weight management service.
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, a prescription medicine used for type 2 diabetes in certain circumstances and for weight management in eligible adults.
For weight management, tirzepatide is used as part of a wider approach that includes dietary changes and physical activity. It is administered as a once-weekly injection, with the dose generally increased gradually under clinical supervision.
NHS England explains that tirzepatide can help people feel fuller for longer and reduce hunger. Before treatment is prescribed, a healthcare professional should discuss the potential benefits, limitations and possible side effects.
Mounjaro is not simply a medicine that can be requested from a pharmacy without an appropriate prescription. Treatment must be assessed and prescribed by an authorised healthcare professional when the relevant criteria are met.
When Did the NHS Mounjaro Rollout Begin?
The NHS rollout of tirzepatide for weight management began in stages following NICE’s technology appraisal.
NICE recommended tirzepatide for eligible adults with obesity and weight-related health problems. NHS England subsequently introduced a phased implementation approach because the number of people who could potentially meet the full NICE eligibility criteria is considerably larger than the capacity available for immediate treatment.
In specialist weight management services, NHS funding for eligible patients began from 24 March 2025. Primary-care implementation followed from 23 June 2025, with access introduced through prioritised patient cohorts.
This means that the phrase “Mounjaro rollout 2025/26” refers to the first year of the phased primary-care implementation rather than a situation where every eligible person could immediately receive treatment from their GP.
Who Is Eligible for NHS Mounjaro?
NHS eligibility for Mounjaro for weight management is based on clinical criteria rather than BMI alone.
Under NICE’s technology appraisal, tirzepatide is recommended for adults with an initial BMI of at least 35 kg/m² who also have at least one weight-related health condition. For people from certain ethnic backgrounds, including South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds, the BMI threshold is usually reduced by 2.5 kg/m².
Qualifying health conditions can include hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes.
However, meeting the wider NICE eligibility criteria does not necessarily mean that every patient receives immediate access through primary care. The NHS is using a phased approach to prioritise access according to clinical need.
NHS Mounjaro Eligibility in 2025/26
During the first year of primary-care implementation, NHS England prioritised people with the highest level of clinical need.
For 2025/26, the initial primary-care cohort included adults with a BMI of at least 40 kg/m² and at least four qualifying weight-related comorbidities. These include hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes.
The BMI threshold is subject to the ethnicity-related adjustment described in the NHS England guidance.
This prioritisation was designed to allow NHS services to introduce tirzepatide safely while developing the necessary clinical pathways, workforce capacity and support services.
What Changes in 2026/27?
The NHS rollout is expanding beyond the initial 2025/26 cohort.
According to NHS England’s April 2026 interim commissioning guidance, the second funding year, 2026/27, includes Cohort I and Cohort II. Cohort II covers eligible adults with a BMI of 35–39.9 kg/m² who have at least four qualifying weight-related comorbidities.
This does not mean that Mounjaro becomes universally available through every GP practice to anyone who wants weight-loss medication.
Local implementation can depend on the arrangements established by the relevant Integrated Care Board (ICB), and patients still need clinical assessment to determine whether treatment is appropriate.
What Health Conditions Can Affect Eligibility?
The NHS rollout considers several obesity-related health conditions when prioritising access.
These include high blood pressure, abnormal blood lipid levels, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes.
Having one of these conditions may be clinically relevant, but the number and combination of conditions required for a particular rollout cohort can affect whether someone is prioritised for NHS treatment.
For this reason, it is important not to assume that having obesity and one health condition automatically means that you can receive NHS Mounjaro through primary care.
A GP, specialist weight management team or another appropriate healthcare professional can assess your individual circumstances against the current criteria.
How Do You Access NHS Mounjaro?
The route to NHS Mounjaro depends on your eligibility and local service arrangements.
Specialist weight management services can prescribe tirzepatide to eligible patients when a prescribing clinician considers it appropriate. Primary-care access is being introduced through phased local pathways, which can include GP practices and community-based delivery models.
If you think you may meet the criteria, speaking to your GP or relevant NHS weight management service is an appropriate starting point.
Your healthcare professional may assess your BMI, existing medical conditions, current medicines and wider health circumstances before deciding whether referral or treatment is appropriate.
Is NHS Mounjaro Available from a Pharmacy?
A pharmacy can dispense Mounjaro when a valid prescription has been issued, but a pharmacy does not independently decide whether a patient qualifies for NHS-funded Mounjaro for weight management.
This distinction is particularly important for people searching for Mounjaro pharmacy Manchester or a pharmacy in Manchester that supplies weight-loss injections.
The prescription, clinical assessment and funding pathway must come through an appropriate NHS or private prescribing service.
A community pharmacy may be involved in dispensing and supporting patients with their prescribed medication, depending on the local service arrangement.
NHS Mounjaro vs Private Mounjaro Treatment
NHS treatment and private treatment should not be confused.
NHS Mounjaro for weight management is subject to NICE criteria and the NHS England phased access arrangements. A private provider may assess patients under a different prescribing pathway, but private treatment still requires appropriate clinical assessment and must comply with UK prescribing and medicine-supply requirements.
If you are considering a private weight management service in Manchester, check who is responsible for prescribing, what clinical assessment is carried out and what ongoing monitoring and support are included.
Cost alone should not be the deciding factor when choosing a weight management service.
What Support Comes With NHS Mounjaro?
Mounjaro is not intended to be used as a standalone weight-loss solution.
When tirzepatide is prescribed for weight management in primary care, NHS England requires structured wraparound care. This includes clinical support from the prescribing healthcare professional as well as behavioural support covering areas such as nutrition, physical activity and sustainable lifestyle changes.
NHS England states that primary-care patients receive clinical support including regular medicine reviews and monitoring, while behavioural support is also provided through the relevant NHS programme or local service.
This wider support is an important part of safe and effective weight management.
What Should You Know Before Starting Mounjaro?
Mounjaro is a prescription medicine and is not suitable for everyone.
Before treatment, a healthcare professional should review your medical history, current medicines and relevant health circumstances. Pregnancy, breastfeeding and certain medical conditions can affect whether tirzepatide is appropriate.
There can also be important considerations around other medicines. For example, NHS England advises people using tirzepatide who take the contraceptive pill to use an additional method of contraception because the medicine can affect absorption of the pill.
If you are taking Mounjaro and are due to have surgery, you should tell your healthcare team, including the anaesthetist, that you are using tirzepatide.
Never start, stop or change a prescription medicine without discussing it with an appropriate healthcare professional.
Mounjaro Access in Manchester
For people living in Manchester, NHS Mounjaro access is linked to the local NHS pathway and the phased implementation arrangements.
This means that searching for a Manchester pharmacy alone will not establish whether you qualify for NHS-funded Mounjaro. Eligibility needs to be assessed through the appropriate clinical service.
Once treatment has been prescribed, an eligible patient may receive their medication through the dispensing arrangements associated with their NHS pathway.
If you are considering weight management support locally, a local pharmacy in Manchester can also be a useful place to ask about the services it provides, although the pharmacy may not itself be responsible for assessing NHS Mounjaro eligibility.
Finding Pharmacy Services in Manchester
Community pharmacies provide a range of healthcare services, although the exact services available differ between providers.
When searching for pharmacy services in Manchester, patients may be looking for prescription support, vaccinations, weight management services or other healthcare options.
Oldfield Pharmacy serves patients in Manchester and Altrincham and provides a range of pharmacy and healthcare services, including weight management support and other prescription and preventative healthcare services.
If you are comparing a community pharmacy in Manchester for weight management or prescription needs, it is sensible to check exactly which services are provided and whether they are NHS-funded or private.
Does Everyone Who Wants Mounjaro Qualify?
No.
Mounjaro is not automatically available on the NHS simply because someone wants to lose weight or has a BMI above a particular level.
NHS treatment for obesity is based on clinical eligibility, NICE recommendations and the phased implementation arrangements established by NHS England.
The current primary-care rollout is deliberately prioritised according to clinical need. NHS England’s interim guidance states that the initial three-year approach is intended to increase access in stages, with the eligible population expanding through successive cohorts.
This phased approach also gives NHS services time to develop safe prescribing, monitoring and behavioural-support pathways.
What Is the Future of the NHS Mounjaro Rollout?
The NHS England rollout is expected to expand progressively rather than provide universal access immediately.
For the first three years, the planned primary-care cohorts widen from the highest-need patients to additional eligible groups. NHS England’s current guidance estimates that approximately 220,000 people will be included through the initial three-year phased approach, while the wider NICE-eligible population is expected to gain access over a longer period.
The exact timing of access can therefore depend on the patient’s clinical circumstances, local NHS arrangements and the stage of the rollout.
Because the pathway is evolving, anyone considering NHS Mounjaro should check the current criteria rather than relying on information published during the initial 2025 rollout.
NHS Mounjaro Rollout 2025/26: The Key Point
The NHS introduction of Mounjaro for weight management is a significant development in obesity treatment, but access is being phased according to clinical need.
During 2025/26, primary-care access focused on the highest-priority cohort, including adults with BMI 40 or above and at least four qualifying weight-related health conditions. For 2026/27, access expands to include a second cohort involving eligible adults with BMI 35–39.9 and at least four qualifying comorbidities.
If you live in Manchester and think you may qualify, the appropriate starting point is an NHS clinical assessment rather than simply approaching a pharmacy and requesting Mounjaro.
For those exploring wider weight management options, Oldfield Pharmacy provides local pharmacy and healthcare services in Manchester and Altrincham. Patients can check the current services available and discuss appropriate options with the pharmacy team.
Whether treatment is provided through the NHS or privately, Mounjaro should only be used following appropriate clinical assessment and with suitable ongoing support.
